Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

PHASE3CompletedINTERVENTIONAL
Enrollment

2,202

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

July 19, 2023

Study Completion Date

July 19, 2023

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.

BIOLOGICAL

Control Quadrivalent influenza virus vaccine

The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.

Trial Locations (11)

Unknown

Hospital de Puerto Montt, Port Montt

CIMER Center/Center for Medical Research on Respiratory Diseases, Santiago

Clínica Alemana, Santiago

Hospital Clínico UC-Christus, Santiago

Hospital Felix Bulnes, Santiago

Universidad San Sebastián, Santiago

Clinica Alemana de Valdivia, Valdivia

Las Pinas Doctors Hospital, Las Piñas

Tropical Disease Foundation Inc, Makati City

San Juan De Dios Hospital, Pasay

Philippine General Hospital, Manila

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY